Dendreon Corp (NASDAQ:DNDN)

CAPS Rating: 2 out of 5

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.

Results 1 - 20 of 337 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar AMax101 (30.52) Submitted: 6/27/2014 5:36:57 PM : Underperform Start Price: $2.36 DNDN Score: +10.46

The large debt situation at Dendreon coupled with an inadequate amount of revenue will lead to the company having a hard time attracting investors.

Recs

0
Member Avatar bIlluminati (29.86) Submitted: 5/13/2014 11:30:39 AM : Underperform Start Price: $2.04 DNDN Score: -0.80

Not profitable.

Recs

0
Member Avatar grantperry (< 20) Submitted: 5/11/2014 3:56:04 AM : Outperform Start Price: $1.97 DNDN Score: +3.84

This stock is undervalued and has great potential

Recs

0
Member Avatar siri22 (< 20) Submitted: 3/4/2014 1:55:39 PM : Outperform Start Price: $3.08 DNDN Score: -36.35

with Europe and world around corner, this stock will make money

Recs

0
Member Avatar SqwiiTrader (43.94) Submitted: 11/9/2013 10:49:00 AM : Outperform Start Price: $2.60 DNDN Score: -29.52

TOS prediction

Recs

0
Member Avatar Herbstmd (52.76) Submitted: 11/5/2013 3:12:34 PM : Underperform Start Price: $2.57 DNDN Score: +28.87

Nothing new in cancer, and competitors products appear to have advantages. No real expectation of expanded sales.

Recs

0
Member Avatar sosa50 (68.85) Submitted: 10/21/2013 5:24:18 PM : Outperform Start Price: $2.40 DNDN Score: -24.05

Speculative takeover candidate...desperately needs sugar daddy to save a good drug from a marketing and implementation nightmare!

Recs

0
Member Avatar AndrewGreenBull (99.21) Submitted: 8/9/2013 10:03:29 AM : Outperform Start Price: $3.75 DNDN Score: -59.72

Revenue of Provenge actually is not a surprise, once DNDN get a nod from the European Medicine Agency, we will see a rapid growth. The possibility is very high, because DNDN recently got positive opinion from the board. Decision should be made in couple month

Recs

0
Member Avatar BACnumber1 (< 20) Submitted: 3/8/2013 11:21:10 AM : Underperform Start Price: $5.99 DNDN Score: +92.21

Now look. I love most pharma companies. However there is no cure for cancer and very little progress has been made for a cure in the past many years. I am way more bullish on stocks like ARNA and NVO, as diabetes is an epidemic which IS on the other hand gaining momentum....

Recs

0
Member Avatar NHWeston102 (67.18) Submitted: 2/15/2013 1:41:06 PM : Underperform Start Price: $6.19 DNDN Score: +95.80

Peaked and headed down.

Recs

0
Member Avatar wayouy (< 20) Submitted: 2/1/2013 3:51:04 PM : Outperform Start Price: $5.97 DNDN Score: -95.43

price per dose will fall in line with market pricing and sales will increase leading to profitability, plus huge short position makes it worth the risk at this price pint

Recs

0
Member Avatar Frimax32 (< 20) Submitted: 1/4/2013 12:09:59 PM : Outperform Start Price: $6.10 DNDN Score: -100.73

I understand they bottomed out and FDA has become tolerant

Recs

0
Member Avatar rrdas (< 20) Submitted: 10/31/2012 9:33:03 PM : Outperform Start Price: $3.82 DNDN Score: -84.03

Time to buy DNDN. When everyone is scared and its time to be greedy. It will run like PCYC.

Recs

0
Member Avatar islandsunsetter (< 20) Submitted: 6/14/2012 1:47:56 AM : Outperform Start Price: $7.30 DNDN Score: -120.73

Nice strong bounce on lots of good rumors.

Recs

0
Member Avatar FWWright (< 20) Submitted: 6/13/2012 4:44:48 PM : Outperform Start Price: $7.30 DNDN Score: -120.73

I think Provenge will be part of a multiple treatment path for a subset of Prostate cancer patients and thus the product will survive. Also, DNDN has an FDA approved facility that could be used for other personalized-vaccines. Finally, the stock is way oversold and should benefit from some short-covering.

Recs

0
Member Avatar Fishboy1970 (< 20) Submitted: 6/10/2012 8:15:33 PM : Outperform Start Price: $6.36 DNDN Score: -114.33

Zytiga will not get through the FDA and be approved in the pre-chemo setting. ASCO presentation says Provenge goes first!

Recs

0
Member Avatar rparnell76 (< 20) Submitted: 5/3/2012 12:30:03 AM : Outperform Start Price: $11.75 DNDN Score: -123.32

I think they will do well now that they are on the move up. We will see.

Recs

0
Member Avatar rightminded (< 20) Submitted: 3/2/2012 6:23:25 AM : Outperform Start Price: $11.51 DNDN Score: -125.72

StockConsultant - 18

Recs

0
Member Avatar KimLanners (< 20) Submitted: 1/5/2012 1:06:07 PM : Outperform Start Price: $4.25 DNDN Score: -94.96

us biotech

Recs

0
Member Avatar Azurik (< 20) Submitted: 11/2/2011 12:35:25 PM : Outperform Start Price: $10.22 DNDN Score: -139.10

DNDN will outperform as Provenge becomes the blockbuster it should have been, once reimbursement program is clear to doctors.

Featured Broker Partners


Advertisement